GlaxoSmithKline (GSK) is a science-led global health care company with a special purpose: to help people do more, feel better, live longer. In 2014, GSK signed a license agreement with Codexis for use of their proprietary CodeEvolver® protein engineering platform technology to develop novel enzymes for more efficient and sustainable manufacture of GSK’s pharmaceutical and health care products.
Merck is a leading global biopharmaceutical company that has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Under a 2015 technology transfer and licensing agreement, Codexis completed transfer of its proprietary CodeEvolver® protein engineering platform technology to enhance Merck’s capabilities by advancing and expanding the use of custom enzymes in pharmaceutical manufacturing processes.
Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutrition therapy to change the course of health for consumers, patients and its partners in health care. In 2017, Codexis and Nestlé Health Science entered into a strategic collaboration for multiple projects accessing Codexis’ CodeEvolver® protein engineering platform technology to fuel therapeutic and nutritional innovation. The partnership includes a Nestlé Health Science option for the global development of Codexis’ novel enzyme, CDX-6114, for the management of phenylketonuria (PKU). Nestlé Health Science has also secured strategic access to the CodeEvolver® technology for the discovery of biotherapeutics for other metabolic disorders and for the development of novel enzymes for medical nutrition and consumer care products.
Porton Pharma Solutions provides custom API development and cGMP manufacturing services to the global drug industry. In 2018, Codexis and Porton entered into a strategic collaboration to accelerate the creation and commercialization of new, low-cost sustainable manufacturing processes to supply small molecule pharmaceuticals. The partnership reduces costs by improving yields, eliminating processing steps, enhancing capital productivity and/or minimizing consumption of solvents or energy or downstream waste processing. Codexis licenses core elements of its biocatalyst technologies to Porton and provides preferential access to its CodeEvolver® protein engineering platform technology for the creation of new biocatalytic process solutions. In parallel, Porton pledges to utilize the CodeEvolver® technology team and to drive adoption of biocatalyst technologies into its custom contract development and manufacturing offerings.
Contact us if you are interested in partnering with Codexis as we unlock the power of proteins™ and deliver customized solutions.